A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Inclusion Criteria: * Subjects with ECOG 0,1,2,3 * Subjects with pathologically confirmed PCNSL with lesion in brain who progressed after or did not respond to at least 1 line of systemic therapy. PCNSL prior therapy may include HD-MTX, HD-MTX-based regimen, high-dose cytarabine, radiation therapy alone as treatment or as part of consolidation therapy, high-dose therapy with autologous stem cell transplant as part of consolidation therapy, and/or intraocular MTX alone or as part of consolidation therapy * Subject with sufficient function of liver, kidney, heart, lung and hematopoiesis * Subjects with relapsed PCNSL and are able to receive biopsy Exclusion Criteria: * Subjects that are not DLBCL type pathologically * Intraocular PCNSL without evidence of brain disease * Subjects who cannot undergo MRI assessments * Relapsed PCNSL patients who cannot undergo biopsy * Biopsy suggests no significant tumor-infiltration T cell or poor PD-1 expression * Subjects with other malignancy * Subjects with history of any inflammatory CNS diseases * Subjects with an active, known, or suspected autoimmune disease * Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of start of study treatment * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways Other protocol defined inclusion/exclusion criteria could apply